NOVACYT SUCCESSFULLY COMPLETES €2.7M FUNDRAISING

novacyt-financing-english Paris, France and Cambridge, UK – 15 December 2016 – Novacyt (ALTERNEXT: ALNOV), an international specialist in clinical diagnostics, today announces a private equity placement raising gross €2.7m in an oversubscribed issue.

Visit Page

NOVACYT WINS TECHNOLOGY FAST 50 AWARD

novacyt-technology-fast-50-award-english Paris, France and Cambridge, UK – 8 November 2016 – Novacyt (ALTERNEXT: ALNOV), an international specialist in clinical diagnostics, today announces it has won the Ile-de-France award of the Deloitte Technology Fast 50 French programme, an initiative that rewards fast growing companies. The Technology Fast 50 is one of France’s foremost technology award programmes.

Visit Page

NOVACYT HALF YEAR 2016 RESULTS

novacyt-half-year-2016-results-pr-english Paris, France and Cambridge, UK – 27th October 2016 – Novacyt (ALTERNEXT: ALNOV), an international specialist in clinical diagnostics, today announces audited financial results for the six months ended 30th June 2016.Visit Page

NOVACYT SIGNS STRATEGIC ALLIANCE WITH CEPHEID FOR HPV DIAGNOSTICS IN LATIN AMERICA

strategic-alliance-agreement-with-cepheid Paris, France and Cambridge, UK – 4th October 2016 – Novacyt (ALTERNEXT: ALNOV), an international specialist in clinical diagnostics, today announces it has entered into a strategic alliance with Cepheid Inc., a leading international molecular diagnostics company, to introduce a complete Human Papillomavirus (HPV) diagnostic system into Latin America.

Visit Page

Novacyt expands distribution presence in Asia Pacific

Novacyt (ALTERNEXT: ALNOV), an international specialist in cancer and infectious disease diagnostics, today announces that it has appointed MDL Asia Pty Ltd (“MDL” or “MDL Asia”) as its marketing and distribution partner in the Asia Pacific region, excluding Greater China. Download press release

Visit Page